Sign In
Buy BCSF
Bain Capital Specialty Finance Earnings Calls
| Release date | May 11, 2026 |
| EPS estimate | $0.440 |
| EPS actual | $0.420 |
| EPS Surprise | -4.55% |
| Revenue estimate | 65.578M |
| Revenue actual | 66.174M |
| Revenue Surprise | 0.91% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.450 |
| EPS actual | $0.460 |
| EPS Surprise | 2.22% |
| Revenue estimate | 68.484M |
| Revenue actual | 68.2M |
| Revenue Surprise | -0.414% |
| Release date | Nov 10, 2025 |
| EPS estimate | $0.450 |
| EPS actual | $0.450 |
| Revenue estimate | 69.526M |
| Revenue actual | 42.674M |
| Revenue Surprise | -38.62% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.430 |
| EPS actual | $0.470 |
| EPS Surprise | 9.30% |
| Revenue estimate | 66.703M |
| Revenue actual | 73.706M |
| Revenue Surprise | 10.50% |
Last 4 Quarters for Bain Capital Specialty Finance
Below you can see how BCSF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 05, 2025 |
| Price on release | $14.76 |
| EPS estimate | $0.430 |
| EPS actual | $0.470 |
| EPS surprise | 9.30% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $14.92 |
| Jul 31, 2025 | $15.00 |
| Aug 01, 2025 | $14.72 |
| Aug 04, 2025 | $14.68 |
| Aug 05, 2025 | $14.76 |
| Aug 06, 2025 | $15.15 |
| Aug 07, 2025 | $14.94 |
| Aug 08, 2025 | $15.20 |
| Aug 11, 2025 | $15.10 |
| 4 days before | -1.07% |
| 4 days after | 2.30% |
| On release day | 2.64% |
| Change in period | 1.21% |
| Release date | Nov 10, 2025 |
| Price on release | $13.92 |
| EPS estimate | $0.450 |
| EPS actual | $0.450 |
| Date | Price |
|---|---|
| Nov 04, 2025 | $13.97 |
| Nov 05, 2025 | $13.94 |
| Nov 06, 2025 | $13.75 |
| Nov 07, 2025 | $13.89 |
| Nov 10, 2025 | $13.92 |
| Nov 11, 2025 | $13.73 |
| Nov 12, 2025 | $14.01 |
| Nov 13, 2025 | $13.87 |
| Nov 14, 2025 | $13.89 |
| 4 days before | -0.358% |
| 4 days after | -0.216% |
| On release day | -1.36% |
| Change in period | -0.573% |
| Release date | Feb 26, 2026 |
| Price on release | $12.75 |
| EPS estimate | $0.450 |
| EPS actual | $0.460 |
| EPS surprise | 2.22% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $13.50 |
| Feb 23, 2026 | $12.83 |
| Feb 24, 2026 | $13.14 |
| Feb 25, 2026 | $13.27 |
| Feb 26, 2026 | $12.75 |
| Feb 27, 2026 | $12.91 |
| Mar 02, 2026 | $12.87 |
| Mar 03, 2026 | $12.56 |
| Mar 04, 2026 | $12.75 |
| 4 days before | -5.56% |
| 4 days after | 0% |
| On release day | 1.25% |
| Change in period | -5.56% |
| Release date | May 11, 2026 |
| Price on release | $13.30 |
| EPS estimate | $0.440 |
| EPS actual | $0.420 |
| EPS surprise | -4.55% |
| Date | Price |
|---|---|
| May 05, 2026 | $14.06 |
| May 06, 2026 | $13.95 |
| May 07, 2026 | $13.81 |
| May 08, 2026 | $13.66 |
| May 11, 2026 | $13.30 |
| May 12, 2026 | $13.50 |
| May 13, 2026 | $13.42 |
| May 14, 2026 | $13.42 |
| May 15, 2026 | $13.36 |
| 4 days before | -5.41% |
| 4 days after | 0.451% |
| On release day | 1.50% |
| Change in period | -4.98% |
Bain Capital Specialty Finance Earnings Call Transcript Summary of Q1 2026
Key points for investors:
- Q1 results: Net investment income (NII) per share was $0.42 (annualized ROE 10.0%) and covered the regular dividend. GAAP EPS was $0.05, driven by $24.0M of net realized and unrealized losses largely from idiosyncratic credit marks and market-driven spread/multiple compression. NAV per share was $16.86 (down $0.37 QoQ).
- Dividend & capital policy: Board declared Q2 regular dividend of $0.42 per share (annualized ~10% on Q1 ending book value). Management says the dividend is being evaluated quarterly but is comfortable with the $0.42 dividend for Q2.
- Portfolio size & composition: Portfolio fair value $2.5B across 212 companies and 30 industries; highly diversified, average single-name weight ~40 bps. ~66% first-lien debt; ~93% of debt is floating-rate. Software exposure (including adjacencies) ~13% of portfolio.
- Credit quality & metrics: Median borrower net leverage ~4.6x EBITDA (improved QoQ), median interest coverage ~2.1x. Watch list ~5% of portfolio (stable and idiosyncratic), nonaccruals low at 1.4% (amortized cost). New originations spreads averaged ~550 bps (Q1); market spreads have widened another ~25–50 bps into Q2.
- Activity & liquidity: New fundings $243M (51% new companies / 49% existing), sales & repayments ~$255M (net -$12.2M). Liquidity strong at ~$729M (including $660M undrawn revolver capacity). Net leverage at the BDC level ~1.28x; debt-to-equity ~1.34x. Issued $350M unsecured March 2031 note to prefund 2026 maturities and extend duration.
- Portfolio actions & outlook: Management exited an aviation position (Gale Aviation) during Q1 and emphasized selective, defensive sector focus (food & beverage, business services, health care) and first-lien emphasis. Management believes most software investments have low AI-disruption risk due to selective underwriting focused on mission-critical/vertical software. Buybacks remain under consideration but not executed; Board continues disciplined capital management with focus on dividend sustainability and long-term shareholder value.
